CogniScent provides AI guided early detection of neurodegenerative diseases.
60 million people are affected by Parkinson’s and Alzheimer’s worldwide, with cases doubling in the next 20 years. Diagnosis only occurs at advanced stages of the diseases.
CogniScent develop a novel test for early detection. Using machine learning, they predict a personal risk score based on early symptoms, where smell plays a key role.
They are currently testing our prototype, built on exclusive data from the University Clinic of Dresden. Their test will improve the lives of 2 million diagnosed people per year and help save US $60 billion in healthcare costs in Europe and the US.
